Similarly, fluoxetine, an FDA-approved drug for treating clinical depression, has recently been identified as a direct NLRP3 inhibitor that prevents the NLRP3-ASC assembly [206]. The gene discussed is NLRP3; the disease is depressive symptom measurement.